Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival
Open accessAbstract
PURPOSE: To compare gadoteridol and ferumoxytol for measurement of relative cerebral blood volume (rCBV) in patients with glioblastoma multiforme (GBM) who showed progressive disease at conventional magnetic resonance (MR) imaging after chemo- and radiation therapy (hereafter, chemoradiotherapy) and to correlate rCBV with survival. MATERIALS AND METHODS: Informed consent was obtained from all participants before enrollment in one of four institutional review board-approved protocols. Contrast agent leakage maps and rCBV were derived from perfusion MR imaging with gadoteridol and ferumoxytol in 19 patients with apparently progressive GBM on conventional MR images after chemoradiotherapy. Patients were classified as having high rCBV (>1.75), indicating tumor, and low rCBV (≤ 1.75), indicating pseudoprogression, for each contrast agent separately, and with or without contrast agent leakage correction for imaging with gadoteridol. Statistical analysis was performed by using Kaplan-Meier survival plots with the log-rank test and Cox proportional hazards models. RESULTS: With ferumoxytol, rCBV was low in nine (47%) patients, with median overall survival (mOS) of 591 days, and high rCBV in 10 (53%) patients, with mOS of 163 days. A hazard ratio of 0.098 (P = .004) indicated significantly improved survival. With gadoteridol, rCBV was low in 14 (74%) patients, with mOS of 474 days, and high in five (26%), with mOS of 156 days and a nonsignificant hazard ratio of 0.339 (P = .093). Five patients with mismatched high rCBV with ferumoxytol and low rCBV with gadoteridol had an mOS of 171 days. When leakage correction was applied, rCBV with gadoteridol was significantly associated with survival (hazard ratio, 0.12; P = .003). CONCLUSION: Ferumoxytol as a blood pool agent facilitates differentiation between tumor progression and pseudoprogression, appears to be a good prognostic biomarker, and unlike gadoteridol, does not require contrast agent leakage correction.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807 · see citing works
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660 · see citing works
Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J. F., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,814 · see citing works
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409 · see citing works
Østergaard, L., Weisskoff, R. M., Chesler, D. A., Gyldensted, C., & Rosen, B. R. (1996) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910360510 · Cited by 1,511 · see citing works
Perfusion imaging with NMR contrast agents
Rosen, B. R., Belliveau, J. W., Vevea, J. M., & Brady, T. J. (1990) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910140211 · Cited by 1,141 · see citing works
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
Brandsma, D., Stalpers, L. J. A., Taal, W., Sminia, P., & van den Bent, M. J. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70125-6 · Cited by 1,120 · see citing works
Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings.
Aronen, H. J., Gazit, I. E., Louis, D. N., Buchbinder, B. R., Pardo, F. S., Weisskoff, R. M., Harsh, G. R., Cosgrove, G. R., Halpern, E. F., & Hochberg, F. H. (1994) · Radiology · doi:10.1148/radiology.191.1.8134596 · Cited by 905 · see citing works
Brandes, A. A., Franceschi, E., Tosoni, A., Blatt, V., Pession, A., Tallini, G., Bertorelle, R., Bartolini, S., Calbucci, F., Andreoli, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8163 · Cited by 841 · see citing works
Boxerman, J. L., Schmainda, K. M., & Weisskoff, R. M. (2006) · PubMed · Cited by 644 · see citing works
Glial Neoplasms: Dynamic Contrast-enhanced T2*-weighted MR Imaging
Knopp, E. A., Cha, S., Johnson, G., Mazumdar, A., Golfinos, J. G., Zagzag, D., Miller, D. C., Kelly, P. J., & Kricheff, I. I. (1999) · Radiology · doi:10.1148/radiology.211.3.r99jn46791 · Cited by 592 · see citing works
Law, M., Young, R. J., Babb, J. S., Peccerelli, N., Chheang, S., Gruber, M. L., Miller, D. C., Golfinos, J. G., Zagzag, D., & Johnson, G. (2008) · Radiology · doi:10.1148/radiol.2472070898 · Cited by 531 · see citing works
The Radioresponse of the Central Nervous System: A Dynamic Process
Tofilon, P. J., & Fike, J. R. (2000) · Radiation Research · doi:10.1667/0033-7587(2000)153[0357:trotcn]2.0.co;2 · Cited by 528 · see citing works
Weinstein, J. S., Varallyay, C. G., Dosa, E., Gahramanov, S., Hamilton, B., Rooney, W. D., Muldoon, L. L., & Neuwelt, E. A. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.192 · Cited by 500 · see citing works
Self-citationTaal, W., Brandsma, D., de Bruin, H. G., Bromberg, J. E. C., Swaak‐Kragten, A. T., Smitt, P. A. E. S., van Es, C. A., & van den Bent, M. J. (2008) · Cancer · doi:10.1002/cncr.23562 · Cited by 465 · see citing works
Sugahara, T., Korogi, Y., Kochi, M., Ikushima, I., Hirai, T., Okuda, T., Shigematsu, Y., Liang, L., Ge, Y., Ushio, Y., et al. (1998) · American Journal of Roentgenology · doi:10.2214/ajr.171.6.9843274 · Cited by 456 · see citing works
Lev, M. H., Özsunar, Y., Henson, J. W., Rasheed, A. A., Barest, G. D., Harsh, G. R., Fitzek, M. M., Chiocca, E. A., Rabinov, J. D., Csavoy, A. N., et al. (2004) · PubMed Central · Cited by 409 · see citing works
Barajas, R., Chang, J. S., Segal, M. R., Parsa, A. T., McDermott, M. W., Berger, M. S., & Cha, S. (2009) · Radiology · doi:10.1148/radiol.2532090007 · Cited by 406 · see citing works
Hu, L., Baxter, L. C., Smith, K. A., et al. (2008) · American Journal of Neuroradiology · doi:10.3174/ajnr.a1377 · Cited by 397 · see citing works
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression
de Wit, M. Y., de Bruin, H. G., Eijkenboom, W. M. H., Smitt, P. A. E. S., & van den Bent, M. J. (2004) · Neurology · doi:10.1212/01.wnl.0000133398.11870.9a · Cited by 356 · see citing works
Paulson, E. S., & Schmainda, K. M. (2008) · Radiology · doi:10.1148/radiol.2492071659 · Cited by 327 · see citing works
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression
Box, P. (2005) · Dkgest of the World Latest Medical Information · Cited by 299 · see citing works
Brandes, A. A., Tosoni, A., Spagnolli, F., Frezza, G., Leonardi, M., Calbucci, F., & Franceschi, E. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-008 · Cited by 280 · see citing works
Neuwelt, E. A., Hamilton, B. E., Varallyay, C. G., Rooney, W. R., Edelman, R. D., Jacobs, P. M., & Watnick, S. G. (2009) · Kidney International · doi:10.1038/ki.2008.496 · Cited by 267 · see citing works
MECHANISMS OF RADIATION INJURY TO THE CENTRAL NERVOUS SYSTEM: IMPLICATIONS FOR NEUROPROTECTION
Wong, C. S. (2004) · Molecular Interventions · doi:10.1124/mi.4.5.7 · Cited by 259 · see citing works
Danchaivijitr, N., Waldman, A. D., Tozer, D. J., Benton, C. E., Caseiras, G. B., Tofts, P. S., Rees, J. H., & Jäger, H. R. (2008) · Radiology · doi:10.1148/radiol.2471062089 · Cited by 235 · see citing works
Oh, J., Henry, R. G., Pirzkall, A., Lü, Y., Li, X., Catalaa, I., Chang, S. M., Dillon, W. P., & Nelson, S. J. (2004) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.20039 · Cited by 189 · see citing works
Self-citationHypoxia and Hypoxia-Inducible Factor-1 Target Genes in Central Nervous System Radiation Injury
Nordal, R., Nagy, A., Pintilie, M., & Wong, C. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0426 · Cited by 185 · see citing works
Neuwelt, E. A., Várallyay, C. G., Manninger, S., Solymosi, D., Haluska, M., Hunt, M. A., Nesbit, G., Stevens, A., Jerosch-Herold, M., Jacobs, P. M., et al. (2007) · Neurosurgery · doi:10.1227/01.neu.0000255350.71700.37 · Cited by 184 · see citing works
Self-citationMangla, R., Singh, G., Ziegelitz, D., Milano, M. T., Korones, D. N., Zhong, J., & EKHOLM, S. E. (2010) · Radiology · doi:10.1148/radiol.10091440 · Cited by 173 · see citing works
Hoefnagels, F. W. A., Lagerwaard, F. J., Sánchez, E., et al. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5034-5 · Cited by 168 · see citing works
Tumor vascularity in the brain: evaluation with dynamic susceptibility-contrast MR imaging.
Maeda, M., Itoh, S., Kimura, H., Iwasaki, T., Hayashi, N., Yamamoto, K., Ishii, Y., & Kubota, T. (1993) · Radiology · doi:10.1148/radiology.189.1.8372199 · Cited by 164 · see citing works
Gahramanov, S., Raslan, A. M., Muldoon, L. L., Hamilton, B. E., Rooney, W. D., Várallyay, C. G., Njus, J. M., Haluska, M., & Neuwelt, E. A. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.10.072 · Cited by 151 · see citing works
Self-citationHu, L., Baxter, L. C., Pinnaduwage, D. S., et al. (2009) · American Journal of Neuroradiology · doi:10.3174/ajnr.a1787 · Cited by 145 · see citing works
Box, P. (2010) · International Journal of Medical Radiology · Cited by 140 · see citing works
Cao, Y., Tsien, C. I., Nagesh, V., Junck, L., Haken, R. K. T., Ross, B. D., Chenevert, T. L., & Lawrence, T. S. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.09.001 · Cited by 135 · see citing works
Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression
Gerstner, E. R., McNamara, M. B., Norden, A. D., LaFrankie, D. C., & Wen, P. Y. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9809-4 · Cited by 124 · see citing works
Canadian Recommendations for the Treatment of Glioblastoma Multiforme
Mason, W. P., Maestro, R. F. D., Eisenstat, D. D., Forsyth, P. A., Fulton, D. S., Laperrière, N., Macdonald, D. R., Perry, J., & Thiessen, B. A. (2007) · Current Oncology · doi:10.3747/co.2007.119 · Cited by 123 · see citing works
Hu, L., Eschbacher, J. M., Dueck, A. C., Heiserman, J. E., Liu, S., Karis, J. P., Smith, K. A., Shapiro, W. R., Pinnaduwage, D. S., Coons, S. W., et al. (2011) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2743 · Cited by 123 · see citing works
Perfusion MR Imaging of Brain Tumors
Cha, S. (2004) · Topics in Magnetic Resonance Imaging · doi:10.1097/00002142-200410000-00002 · Cited by 111 · see citing works
Várallyay, C. G., Muldoon, L. L., Gahramanov, S., Wu, Y. J., Goodman, J. A., Li, X., Pike, M. M., & Neuwelt, E. A. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2008.162 · Cited by 80 · see citing works
Self-citationPopulation-Based Study of Pseudoprogression after Chemoradiotherapy in GBM
Roldán, G. B., Scott, J. N., McIntyre, J. B., Dharmawardene, M., de Robles, P. A., Magliocco, A. M., Yan, E., Parney, I. F., Forsyth, P. A., Cairncross, J. G., et al. (2009) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100008131 · Cited by 64 · see citing works
Uematsu, H., & Maeda, M. (2005) · European Radiology · doi:10.1007/s00330-005-2807-9 · Cited by 58 · see citing works
Heiland, S., Benner, T., Debus, J., et al. (1999) · Magnetic Resonance Imaging · doi:10.1016/s0730-725x(98)00149-0 · Cited by 55 · see citing works
Gahramanov, S., Muldoon, L. L., Li, X., & Neuwelt, E. A. (2011) · Radiology · doi:10.1148/radiol.11103503 · Cited by 46 · see citing works
Self-citationPerfusion MR Imaging: Moving Forward
Sorensen, A. G. (2008) · Radiology · doi:10.1148/radiol.2492081429 · Cited by 21 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications
Dadfar, S. M., Roemhild, K., Drude, N. I., von Stillfried, S., Knüchel, R., Kiessling, F., & Lammers, T. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.01.005 · Cited by 1,181 · see citing works
Current and potential imaging applications of ferumoxytol for magnetic resonance imaging
Toth, G. B., Varallyay, C. G., Horvath, A., Bashir, M. R., Choyke, P. L., Daldrup-Link, H. E., Dosa, E., Finn, J. P., Gahramanov, S., Harisinghani, M., et al. (2017) · Kidney International · doi:10.1016/j.kint.2016.12.037 · Cited by 317 · see citing works
Self-citationWáng, Y. X. J., & Idée, J.-M. (2017) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims.2017.02.09 · Cited by 247 · see citing works
Clinical applications of iron oxide nanoparticles for magnetic resonance imaging of brain tumors
Iv, M., Telischak, N., Feng, D., Holdsworth, S. J., Yeom, K. W., & Daldrup-Link, H. E. (2015) · Nanomedicine · doi:10.2217/nnm.14.203 · Cited by 134 · see citing works
Sonni, I., Garibotto, V., Iagaru, A., Das, D., & Massoud, T. (2018) · PET/MRI in Oncology · doi:10.1007/978-3-319-68517-5_11 · Cited by 3 · see citing works
- Authors
- Gahramanov, S., Muldoon, L. L., Varallyay, C. G., Li, X., Kraemer, D. F., Fu, R., Hamilton, B. E., Rooney, W. D., & Neuwelt, E. A.
- Affiliations
- Oregon Health & Science University (US)
- Oregon State University (US)
- Portland VA Medical Center (US)
- ORCID
- Venue
- Radiology
- Published
- 2013-03
- Volume
- 266
- Issue
- 3
- Pages
- 842-852
- ISSN
- 0033-8419 (ISSN-L)
- 1527-1315
- PMC
- PMC3579176
- OpenAlex
- W2163203871
- Cited by
- 162
- References
- 46
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 6 · 2023: 7 · 2022: 11 · 2021: 8 · 2020: 10 · 2019: 8 · 2018: 19 · 2017: 14 · 2016: 29 · 2015: 24 · 2014: 15 · 2013: 5
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Radiology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (NS044687)
- National Cancer Institute (R01CA137488)
- National Institute of Neurological Disorders and Stroke (R01NS053468, R01NS044687)
- National Institute of Biomedical Imaging and Bioengineering (R01EB007258)
- Topics
- Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced MRI Techniques and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › MRI in cancer diagnosis
- Keywords
- glioblastoma, pseudoprogression, perfusion MRI, ferumoxytol, gadoteridol, relative cerebral blood volume, blood pool agents, chemoradiotherapy, overall survival, prognostic factors, iron oxide contrast agents, contrast-enhanced MRI, treatment response assessment
- MeSH terms
- Adult, Aged, Brain Neoplasms, Contrast Media, Female, Gadolinium, Heterocyclic Compounds, Humans, Male, Middle Aged, Organometallic Compounds, Prognosis, Sensitivity and Specificity, Statistics as Topic, Reproducibility of Results, Survival Rate, Survival Analysis, Treatment Outcome, Risk Assessment, Magnetic Resonance Angiography, Ferrosoferric Oxide, Chemoradiotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
